Clinical Trial Update: Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 randomized, double-blind, placebo-controlled trial of NRP104 in children aged 6-12 with Attention Deficit Hypera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• NRP104

Snippet

Sponsor: New River Pharmaceuticals | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED